Table 1.
Patient's demographic and clinical characteristics
| Item | Total number (N) = 31(%) | |
| Age, mean ± SD years | 41.7 ± 12.8 years | |
| Sex | ||
| Male | 6 (19.4) | |
| Female | 25 (80.6) | |
| Diagnoses | ||
| SLE | 17 (54.8) | |
| RA | 10 (32.3) | |
| MCTD | 4 (12.9) | |
| Disease Duration | 90.8 ± 60.1 months | |
| Comorbidity | ||
| Hypertension | 10 (32.2) | |
| Diabetes | 5(16.1) | |
| Renal disease | 2 (6.5) | |
| Others, e.g., asthma, lung disease | 4 (12.9) | |
| None | 10 (32.2) | |
| Region | ||
| Greater Accra | 14 (45.2) | |
| Ashanti | 3 (9.7) | |
| Volta | 6 (19.4) | |
| Eastern | 4 (12.9) | |
| Central | 3 (9.7) | |
| Oti | 1 (3.2) | |
| Occupation | ||
| Administrative assistant | 1 (3.2) | |
| Civil servant | 1 (3.2) | |
| HR professional | 1 (3.2) | |
| Quality assurance officer | 1 (3.2) | |
| Not working | 27 (87.1) | |
| Medication | ||
| Prednisolone | Yes | 26 (83.9) |
| No | 5 (16.1) | |
| Hydroxychloroquine | Yes | 26 (83.9) |
| No | 5 (16.1) | |
| Methotrexate | Yes | 7 (22.6) |
| No | 24 (77.4) | |
| Azathioprine | Yes | 6 (19.4) |
| No | 25 (80.6) | |
| Cyclophosphamide | Yes | 4 (12.9) |
| No | 27 (87.1) | |
| Mycophenolate Mofetil | Yes | 2 (6.5) |
| No | 29 (93.5) | |
| Omeprazole | Yes | 15 (48.4) |
| No | 16 (51.6) | |
| Calcium | Yes | 16 (51.6) |
| No | 15 (48.4) | |
| COVID-19 symptoms | ||
| Fever | Yes | 22 (71.0) |
| No | 9 (29.0) | |
| Headache | Yes | 22 (71.0) |
| No | 9 (29.0) | |
| Cough | Yes | 21 (67.7) |
| No | 10 (32.3) | |
| Sore throat | Yes | 12 (38.7) |
| No | 19 (61.3) | |
| Muscle pain | Yes | 11 (35.5) |
| No | 20 (64.5) | |
| Difficulty breathing | Yes | 9 (29.0) |
| No | 22 (71.0) | |
| Chills | Yes | 8 (25.8) |
| No | 23 (74.2) | |
| Runny nose | Yes | 7 (22.6) |
| No | 24 (77.4) | |
| Loss of smell/taste | Yes | 7 (22.6) |
| No | 24 (77.4) | |
| Diarrhea | Yes | 4 (12.9) |
| No | 27 (87.1) | |
| Abdominal pain | Yes | 3 (9.7) |
| No | 28 (90.3) | |
| Nausea/vomiting | Yes | 3 (9.7) |
| No | 28 (90.3) | |